http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S6013790-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da54f7ebbd2d9d8a82f92aca4d1b4e48 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 1984-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcebacb8f3195252a26da417d35af800 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb936b470301b5bf0fbb565dede4922a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d65b21ae999bc818f0a9bf57bf7c308 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19c8c40c7e8ed2eb530aa421b6e4344d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d322c7978a58f72cb5bb404361f9c6a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_532a5ecd71ebf6700a6863502dcaa1c1 |
| publicationDate | 1985-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-S6013790-A |
| titleOfInvention | Novel substituted beta-carboline, manufacture and central nervous system effecting agent containing same |
| abstract | Substituted beta -carbolines of the formula I n<IMAGE>n in whichn R<3> denotes the 5-oxadiazolyl radical n<IMAGE>n where R' has the meaning C1-3-alkyl and C3-C6-alkyl andn the alkoxycarbonyl radical -COOR'' where R'' has the meaning C1-4-alkyl,n R<4> denotes hydrogen, methyl, ethyl and methoxymethyl andn R<A> denotes the aryl radical n<IMAGE>n and the aralkyl radical n<IMAGE>n where X has the meaning C1-12-alkyl, it being possible for the alkyl radical to be straight-chain, branched, saturated or unsaturated and for a CH2 group to be substituted by a carbonyl group, and where R''' has the meaning fluorine, chlorine, bromine or iodine, C1-3-alkyl, C1-3-alkoxy, C1-5-acyloxy, phenyl, C2-5-alkylenedioxy, trifluoromethyl, nitrilo, nitro or an amino group -NR<IV>R<V> wheren R<IV> and R<V> have the meaning hydrogen, C1-3-alkyl, C1-5-acyl or phenyl, it being possible for R<IV> and R<V> to be identical or different and to form a 3-6-membered hetero ring system together with the amino nitrogen atom,n it being possible for the substituent R''' to occur once or more on the aryl radical in an identical or different manner, and a process for their preparation are described. n<??>The compounds have an action on the central nervous system and are thus suitable as psychopharmaceuticals. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S62221684-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S62167780-A |
| priorityDate | 1983-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.